ArticleACS omega2026
Electrosprayed Shellac-Salt Nanoparticles for Improved Intestinal Dissolution and pH-Responsive Drug Release.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop and optimize shellac-salt (SHL-salt) nanoparticles using the electrospraying technique. A central composite design (CCD) was employed to systematically evaluate the effects of shellac concentration, salt conversion degree, and applied electrical voltage on the average particle size, size distribution, and solubility of the prepared nanoparticles. The optimized formulationcomprising 20% (w/w) shellac, 100% salt conversion degree, and an applied voltage of 15 kVproduced nanoparticles with an average particle size of 758.00 nm and a narrow size distribution of approximately 94.44 nm, along with markedly enhanced solubility at intestinal pH 6.8. Diclofenac sodium (DS) was selected as a model drug to assess encapsulation efficiency, drug loading capacity, and drug release behavior following incorporation into the nanoparticle matrix. The optimized nanoparticles exhibited high encapsulation efficiency (97.63%) with a drug loading capacity of 4.88%. Physicochemical characterization using powder X-ray diffractometry (PXRD) and Fourier-transform infrared spectroscopy (FTIR) confirmed that DS was present in an amorphous state and molecularly dispersed within the shellac-salt matrix. In vitro dissolution studies under simulated gastrointestinal conditions showed no drug release in acidic medium; however, DS-loaded shellac-salt nanoparticles exhibited significantly faster drug release at intestinal pH compared with DS-loaded shellac acid nanoparticles. In summary, the application of CCD-based statistical optimization enabled the successful fabrication of drug-loaded shellac nanoparticles, demonstrating their potential as promising carriers for improved intestinal dissolution.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.